Biomarkers in asthmatic patients: Has their time come to direct treatment?
Biomarkers in asthmatic patients: Has their time come to direct treatment?
复制标题
DOI：
10.1016/j.jaci.2016.03.009
复制
发表时间：
2016-05-01
影响因子：
14.2
通讯作者：
Busse, William W.
中科院分区：
文献类型：
--
作者：
Berry, Alalia;Busse, William W.
哮喘是一种异质性疾病，具有多种表型，具有可变的风险因素和对治疗的反应。轻度至中度哮喘通常对传统药物有反应，而严重的疾病可能对吸入性皮质类固醇、长效β受体激动剂和白三烯受体拮抗剂无效。对哮喘的可变表型进行了强有力的研究。生物标志物有助于确定不同哮喘表型的特定病理生理学，并确定潜在的治疗靶点。下面的综述将讨论目前使用的生物标志物诊断哮喘，分诊患者的疾病的严重程度，和治疗的潜在疗效。该信息可用于定义更可能对吸入性皮质类固醇或生物制剂有反应的某些患者人群。随着对患者表型和内在型以及针对特定类别哮喘的生物制剂的了解的出现，为哮喘患者提供个性化护理的能力将随之而来。
Asthma is a heterogeneous disease with multiple phenotypes that have variable risk factors and responses to therapeutics. Mild-to-moderate asthma often responds to traditional medications, whereas severe disease can be refractory to inhaled corticosteroids, long-acting beta-agonists, and leukotriene receptor antagonists. There is robust research into the variable phenotypes of asthma. Biomarkers help define the specific pathophysiology of different asthma phenotypes and identify potential therapeutic targets. The following review will discuss the current use of biomarkers for the diagnosis of asthma, triaging the severity of a patient's disease, and the potential efficacy of treatments. This information can be used to define certain patient populations that are more likely to respond to inhaled corticosteroids or biologics. As knowledge of patient phenotypes and endotypes and biological agents to target specific classes of asthma emerge, the ability to provide personalized care to asthmatic patients will follow.